HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

XJB-5-131

hemigramicidin-TEMPO conjugate; TEMPO - 2,2,6,6-tetramethyl-4-piperidine-N-oxide; structure in first source

Networked: 11 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Heterocyclic Oxides
  - Cyclic N-Oxides: 3
    - XJB-5-131: 11

Experts

1.	Wipf, Peter: 9 articles (01/2022 - 09/2007)
2.	McMurray, Cynthia T: 4 articles (01/2022 - 11/2012)
3.	Javadov, Sabzali: 3 articles (10/2020 - 12/2014)
4.	Ayala-Peña, Sylvette: 3 articles (01/2016 - 11/2012)
5.	Skoda, Erin M: 3 articles (12/2014 - 11/2012)
6.	Kagan, Valerian E: 3 articles (07/2010 - 09/2007)
7.	Tyurina, Yulia Y: 3 articles (07/2010 - 09/2007)
8.	Xun, Zhiyin: 2 articles (01/2022 - 11/2012)
9.	Jang, Sehwan: 2 articles (01/2017 - 12/2014)
10.	Delude, Russell L: 2 articles (09/2007 - 09/2007)

Related Diseases

1.	Kidney Diseases (Kidney Disease) 01/01/2020 - "Taken together, ferroptosis plays an important role in renal tubular injury and the inhibition of ferroptosis by XJB-5-131 is a promising therapeutic strategy for protection against renal tubular cell injury in kidney diseases."
2.	Ischemia 12/01/2014 - "In this study, we evaluated the effects of XJB-5-131 (XJB), a mitochondria-targeted ROS and electron scavenger, on cardiac resistance to ischemia-reperfusion (IR)-induced oxidative stress in aged rats. " 01/01/2017 - "The relationship between mitochondrial PTP, ROS, and SCs was investigated using Langendorff-perfused rat hearts subjected to global ischemia (25 min) followed by short-time (5 min) or long-time (60 min) reperfusion in the presence or absence of the PTP inhibitor, sanglifehrin A (SfA), and the mitochondrial targeted ROS and electron scavenger, XJB-5-131. " 09/03/2013 - "Dexamethasone and XJB-5-131 each diminished the loss of evoked dopamine activity, diminished ischemia, diminished the loss of neuronal nuclei, diminished the appearance of extravasated macrophages, and diminished the loss of dopamine axons and terminals next to the probes. "
3.	Huntington Disease (Huntington's Disease) 01/01/2022 - "A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington's Disease." 01/01/2016 - "XJB-5-131 prevents the onset of motor decline in an HdhQ(150/150) mouse model for Huntington's disease (HD) if treatment starts early. " 11/29/2012 - "Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease." 01/01/2022 - "Because mitochondrial decline is a common and central feature of toxicity, the favorable properties of XJB-5-131 are likely to be useful in treating Huntington's disease and a wide spectrum of neurodegenerative diseases for which oxidative damage is a key component. "
4.	Disease Progression 01/01/2016 - "Here, we report that XJB-5-131 attenuates or reverses disease progression if treatment occurs after disease onset. " 01/01/2022 - "By quenching reactive oxygen species, XJB-5-131 breaks the cycle between the rise in oxidative damage during disease progression and the somatic growth of the CAG repeat which depends on oxidation."
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2022 - "Because mitochondrial decline is a common and central feature of toxicity, the favorable properties of XJB-5-131 are likely to be useful in treating Huntington's disease and a wide spectrum of neurodegenerative diseases for which oxidative damage is a key component. "

Related Drugs and Biologics

1.	Gramicidin (Gramicidin A)
2.	Caspase 3 (Caspase-3)
3.	Reactive Oxygen Species (Oxygen Radicals)
4.	Peptides (Polypeptides)
5.	Free Radicals
6.	Dopamine (Intropin)
7.	Mitochondrial DNA (mtDNA)
8.	Dexamethasone (Maxidex)
9.	Antioxidants
10.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Resuscitation
2.	Treatment Delay